Oobli Gains FDA Nod for Sweet Protein Monellin, Expands Portfolio of Zero Glycemic Impact Sweeteners

Oobli, a US sweet protein developer, has gained FDA approval for its monellin sweet protein, produced through precision fermentation. This approval allows Oobli to expand its portfolio of zero glycemic impact sweeteners, offering healthier alternatives to traditional sugar and artificial sweeteners. With monellin being significantly sweeter than sugar, companies can now focus on reducing sugar without compromising taste, thanks to Oobli's innovative sweet proteins.

The brand, based in California, claims to be the first company developing a platform for multiple sweet proteins, with four sweet proteins available. These proteins, produced through fermentation, have no glycemic impact or adverse effects on the gut microbiome, making them a sustainable and healthy choice for food and beverage products. Major food companies, like Grupo Bimbo, are already working with Oobli to incorporate their sweeteners into formulations, with products expected to launch in 2025. Additionally, Oobli has welcomed new board members with expertise in technology, science, and marketing to further grow their protein platform and bring change to the food system.